Nektar TherapeuticsNKTR
13F holders, Q2 2025 (June 30)9holders −148
3new positions
75sold out
$14.68avg. 13F price*
At the end of Q2 2025, 9 institutions reported holding Nektar Therapeutics (NKTR) in their 13F filings, down 148 from Q1 2025. 3 opened new positions and 75 sold out. The largest holders were Essential Partners LLC ($96K), Parallel Advisors, LLC ($27K) and EverSource Wealth Advisors, LLC ($21K).
- Company
- Nektar Therapeutics
- CUSIP
- 640268108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $5K |
| Exits | 75 | $16.8M |
All 13F filers, Q1 2025 → Q2 2025: 4,575 shares bought and 24,722,204 shares sold, net −24,717,629 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Essential Partners LLC | 0.04% | — | 3,732 | $96K |
| Parallel Advisors, LLC | 0.00% | Reduce -93.3% | 1,053 | $27K |
| EverSource Wealth Advisors, LLC | 0.00% | Reduce -41.8% | 810 | $21K |
| IFP Advisors, Inc | 0.00% | New | 4,516 | $3K |
| Rise Advisors, LLC | 0.00% | New | 49 | $1K |
| AllSquare Wealth Management LLC | 0.00% | Reduce -93.5% | 18 | $465 |
| Nova Wealth Management, Inc. | 0.00% | New | 10 | $258 |
| LRI Investments, LLC | 0.00% | Reduce -93.8% | 1 | $26 |
| Huntington National Bank | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is NKTR's weight in each manager's 13F, not the share of Nektar Therapeutics the manager owns.